January 22, 2018 / 12:08 PM / 3 months ago

BRIEF-Titan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization

Titan Pharmaceuticals Inc:

* TITAN IN DISCUSSIONS WITH BRAEBURN REGARDING U.S. PROBUPHINE® COMMERCIALIZATION

* TITAN PHARMACEUTICALS - ‍HAS BEEN IN PRELIMINARY DISCUSSIONS WITH BRAEBURN FOR RETURN OF U.S. COMMERCIALIZATION RIGHTS TO PROBUPHINE​

* TITAN PHARMACEUTICALS - ‍HAS RETAINED CANACCORD GENUITY TO ASSIST IN EFFORT AS PART OF EVALUATION OF STRATEGIC AND FINANCIAL ALTERNATIVES​

* TITAN PHARMACEUTICALS - ‍BELIEVES IT IS APPROPRIATE TO SEEK A NEW PARTNER THAT CAN BETTER FOCUS ON SUCCESSFUL COMMERCIALIZATION STRATEGY FOR PROBUPHINE​

* TITAN PHARMACEUTICALS - BRAEBURN’S RECEIPT OF CRL FROM U.S. FDA FOR BUPRENORPHINE PRODUCT NDA LIKELY TO NEGATIVELY IMPACT ITS PROBUPHINE MARKETING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below